Patrick Trucchio has given his Buy rating due to a combination of factors that highlight the promising potential of Mind Medicine’s MM120 treatment. The company is advancing MM120, a ...

Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide D-tartrate (LSD), MM120 orally disintegrating tablets (ODT), for the ...

Mind Medicine (MNMD) announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120 as a treatment for anxiety.

T he MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has ...

Shares of Mind Medicine Inc. (MNMD) surged more than 15% Friday afternoon, on track for their best session since April 2024, ...

Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT Business Wire • last month MindMed Scientific Presentations at American College of ...

And, in March 2024, the FDA granted breakthrough designation for Mind Medicines (MindMed), MM120, (LSD D-tartrate) for the treatment of generalised anxiety disorder (GAD). In April 2024 ...

Fort St. Lucie, FL (February 22, 2025) – A vehicle crash with injuries occurred on I-95 SB at Mile Marker 120 in St. Lucie County on Saturday night. The accident was reported at 10:14 p.m., prompting ...

MM120 ODT uses Catalent’s Zydis ODT technology. Credit: MindMed Inc./Business Wire. Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of ...

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for ...